Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial
Marjan Tabesh, Mariam Hachem, Lik-Hui Lau, Karen Borschmann, Leonid Churilov, Sarah AL Price, Priya Sumithran, Geoffrey Donnan, Jeffrey Zajac, Vincent Thijs, Elif Ekinci
JOURNAL OF CLINICAL NEUROSCIENCE | ELSEVIER SCI LTD | Published : 2021
AIMS: Pre-diabetes is a common condition that affects about 16.4% of Australian adults. Hyperglycaemia is a strong risk factor for the development of stroke. Metformin XR is an approved medication to treat type 2 diabetes in Australia but not pre-diabetes. Additionally, whether it is tolerated following a stroke is unclear. In this pilot study, we aimed to assess the feasibility of Metformin XR in people with stroke and pre-diabetes. METHODS: In this PROBE design trial, people who had recent stroke (within 3 months) with pre-diabetes were randomized to either the active arm (n = 13) receiving usual care plus Metformin XR (500 mg daily increased to a total daily dose of 1500 mg) or the contro..View full abstract
This project was funded by the Stroke Foundation, Small Project Grant.